title: Pathological response to preoperative chemoradiation worsens with anemia in non-small cell lung cancer patients.
abstract: OBJECTIVE
  Positive links between hemoglobin level and therapeutic tumor response are well documented in carcinoma of the cervix and the head and neck, but little evidence of such a link exists for lung cancer. We analyzed our series of patients treated with preoperative chemoradiation for stage IIIA non-small cell lung carcinoma.
  
  
  METHODS
  Between June 1992 and February 2000, 41 consecutive patients with clinical stage IIIA (N2, documented by mediastinoscopy or another invasive procedure) non-small cell lung carcinoma received preoperative-intent chemoradiation. The median preoperative radiation dose was 48.6 Gy, and all patients received cisplatin- or paclitaxel-based chemotherapy. Response was graded on a four point scale: (1) progressive disease before surgery and/or technically inoperable; (2) stable disease with resection performed, but specimen containing > 50% viable tumor; (3) partial response with specimen containing < 50% tumor; and (4) complete response or near-complete response: RO resection with no residual carcinoma or pT1NO with only microscopic residual foci. Pretreatment hemoglobin values were correlated with pathological outcome using ANOVA and the non-parametric test for trend across ordered groups.
  
  
  RESULTS
  The mean hemoglobin level for groups 1 through 4 was 11.8, 12.1, 12.5, and 13.2 respectively, and the association was statistically significant. If the analysis was limited to patients actually undergoing surgery (eliminating group 1), the association remained significant. The nonparametric test for trend across ordered groups was also significant with and without group 1.
  
  
  CONCLUSIONS
  Our analysis supports the hypothesis that response to chemoradiation of non-small cell lung carcinoma improves with increasing hemoglobin levels.
authors.affiliation: Radiation Oncology Centers, a division of Radiological Associates of Sacramento Medical Group, California, USA.
authors.forename: Theodore J
authors.initials: TJ
authors.lastname: Robnett
authors.forename: Mitchell
authors.initials: M
authors.lastname: Machtay
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Hahn
authors.forename: Joseph B
authors.initials: JB
authors.lastname: Shrager
authors.forename: Joseph S
authors.initials: JS
authors.lastname: Friedberg
authors.forename: Larry R
authors.initials: LR
authors.lastname: Kaiser
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000740:Anemia / Q000097:blood / Q000150:complications* / Q000209:etiology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood* / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006441:Hemoglobin A / Q000378:metabolism*; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood* / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000627:therapeutic use; D011300:Preoperative Care
chemical_list: D006441:Hemoglobin A; D017239:Paclitaxel